Table 1.
Ferroptosis relevance among various types of cancer.
| Cancer type | Relevance to ferroptosis | Test animals |
|---|---|---|
| Breast | Combined treatment of siramesine and lapatinib induces ferroptosis by upregulating iron levels (Ma et al., 2016) | None |
| Head and neck | Induction of ferroptosis makes cisplatin-resistant cells more sensitive to treatment (Roh et al., 2016); dihydroartemisinin-induced cell death is partially involved in ferroptosis (Lin et al., 2016) | Nude mice/none |
| Acute myeloid leukemia | Erastin enhances the sensitivity of AML cells to cytarabine and doxorubicin (Yu et al., 2015) | None |
| Pancreatic ductal adenocarcinoma | Artesunate (ART) induces cell death through ferroptosis dependent upon antioxidant homeostasis and increased sensitivity to free intracellular iron (Eling et al., 2015) | None |
| Ovarian | The antiproliferative and cytotoxic effects of ART are partially due to ferroptosis (Greenshields et al., 2016) | C57BL/6 mice |
| Hepatocellular carcinoma | The cytotoxic effects of sorafenib involves ferroptosis; inhibition of the p62-Keap1-NRF2 pathway increases the anticancer activities of erastin and sorafenib; sorafenib-resistant cells are more sensitive to ferroptosis (Galmiche et al., 2014; Louandre et al., 2015; Sun et al., 2016) | Nude mice/C57BL/6 mice |
| Cervical carcinoma Osteosarcoma Prostate adenocarcinoma |
HSPB1 is highly inducible following erastin treatment (Sun et al., 2015) | NOD/SCID mice |
| Diffuse large B cell lymphoma | Particularly sensitive to ferroptotic cell death; dependent on system Xc- (Yang et al., 2014) | None/none |
| Renal cell carcinomas | More sensitive to ferroptosis compared with seven other tissues (Yang et al., 2014) | |
| Non-small cell lung | Erastin enhances the effect of cisplatin in NSCLCs (Yamaguchi et al., 2013) | Nude mice |
| Glioblastoma | xCT and cystathionine γ-lyase are inducible after temozolomide treatment; erastin enhances sensitivity to temozolomide (Chen et al., 2015; Sehm et al., 2016) | None/none |
| Triple-negative breast | Targeting the MUC1-C/xCT pathway could be a therapeutic approach (Hasegawa et al., 2016) | None |